ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis

NCT ID: NCT02982226

Last Updated: 2020-04-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-30
• Study Completion Date: 2021-04-30

Brief Summary

The objective of this clinical trial is to evaluate both the safety and efficacy of the ReNu™ injection on pain and inflammation in subjects diagnosed with plantar fasciitis as compared to a Corticosteroid Injection which is considered standard of care.

Detailed Description

This is a two (2) arm evaluation in 150 subjects with plantar fasciitis. Patients will be treated with ReNu™(study treatment) or Corticosteroids (control).

At each follow-up visit, concomitant medications and adverse events shall be collected from each subject, and each subject shall complete following questionnaires:

• AOFAS Ankle-Hindfoot Score (AOFAS-AHS)
• Visual Analog Score (VAS)
• Single Answer Numeric Evaluation (SANE)
• Subject Satisfaction Score (at the 6 Month Follow Ups ONLY)

The subjects will be assessed at Baseline (pre-injection) using these scales and again at all subsequent study follow-up visits.

Conditions

Fasciitis, Plantar

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

ReNu Injection

Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

Group Type: EXPERIMENTAL

ReNu Injection

Intervention Type: OTHER

ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

Corticosteroid Injection

Plantar Fascia injection with Corticosteroids.

Group Type: ACTIVE_COMPARATOR

Corticosteroid Injection

Intervention Type: OTHER

Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis

Interventions

ReNu Injection

ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

Intervention Type: OTHER

Corticosteroid Injection

Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Ages 18 to 75 inclusive

2. BMI less than 40

3. Actively practicing a contraception method, abstinent, surgically sterile, or post-menopausal (defined as no menses for a minimum of 12 months)

4. Reporting heel pain of >6 on a verbally administered 1-10 pain scale where 1 is no pain and 10 is extreme pain

5. Diagnosed with plantar fasciitis in either foot

6. Completed a minimum of two months of conservative, non-injection treatment/therapies (i.e., activity modification, icing, NSAIDs, orthotics, physical therapy, etc.)

Exclusion Criteria

1. Prior surgery on the affected foot

2. Prior injection treatment for plantar fasciitis within the past 6 months with steroids or tissue engineered materials just in the site seeking treatment

3. Clinical signs and symptoms of infection of foot in question

4. Evidence of significant neurological disease of either foot

5. Non-ambulatory

6. Presence of comorbidities that can be confused with or can exacerbate the condition including, but not limited to the following:

• Calcaneal stress fracture
• Nerve entrapment syndrome, such as Baxter's Nerve Entrapment or Tarsal Tunnel Syndrome
• Plantar Fascial rupture
• Systemic disorders associated with enthesiopathy, i.e., Gout, Reiter's syndrome, rheumatoid arthritis, etc.
• Achilles tendonitis
• Fat Pad Atrophy
• Fibromyalgia
• Diabetic Neuropathy

7. Pregnant, pregnant within the past six (6) months, breast feeding and/or desire to become pregnant during the course of the study, as verified by urine pregnancy test within one week prior to injection.

8. Has taken NSAID medication within the past 14 days, or other pain medication in the past day

9. History of more than two (2) weeks treatment with immuno-suppressants, including systemic corticosteroids or cytotoxic chemotherapy within one month prior to initial screening, or has receive such medications during the screening period, or are anticipated to require such medications during the course of the study.

10. Taking any investigational drug(s) or therapeutic device(s) within 30 days preceding screening

11. History of radiation therapy of the affected foot

12. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV

13. Involved in a Worker's Compensation Claim of any kind

14. Unable to understand the objectives of the trial

15. Presence of any condition(s) which, in the opinion of the investigator, would compromise the subject's ability to complete this study

16. Having a known history of poor adherence with medical treatment.

17. Express an unwillingness to receive human allograft tissue

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MileStone Research Organization

INDUSTRY

Sponsor Role: collaborator

Organogenesis

INDUSTRY

Sponsor Role: collaborator

NuTech Medical, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alan Ng, DPM, FACFAS

Role: PRINCIPAL_INVESTIGATOR

Advanced Orthopedics

Locations

Advanced Orthopedics

Denver, Colorado, United States

Orlando Food and Ankle Clinic

Orlando, Florida, United States

The Iowa Clinic Foot and Ankle Surgery

West Des Moines, Iowa, United States

Lower Extremity Institute of Research & Therapy (LEIRT)

Poland, Ohio, United States

Geisinger

Danville, Pennsylvania, United States

The Vancouvover Clinic

Vancouver, Washington, United States

Countries

United States

Other Identifiers

RD-2015-08-05

Identifier Type: -

Identifier Source: org_study_id